The firm is preparing to test a gene replacement therapy that uses an ultrasound-mediated strategy to deliver a full-length ...

The acquisition will bring navtemadlin, Kartos' late-stage treatment program in myelofibrosis, to Ipsen's pipeline.

Innovent Biologics will commercialize Eli Lilly's CDK4/6 inhibitor Verzenio (abemaciclib) in mainland China, where it is called Verzenios, the companies announced Tuesday. Lilly will retain rights to ...

The agency expects to issue decisions on Vyondys 53 and Amondys 45, which missed their primary endpoint in a confirmatory trial, by February 2027.

The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...

The European Commission on Monday approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as a tissue-agnostic treatment for previously treated patients with unresectable or ...

The firm also said it completed enrollment in the Phase III 4FRONT-2 clinical trial of 4D-150 in wet AMD ahead of schedule.

The company is planning to test its oral immunotherapy in over 800 patients with resectable and unresectable tumors.

The firm will use the proceeds to advance its pipeline of RNA medicines, like AX-0810 and AX-0811, and its Axiomer RNA-editing platform.

The CAR-T maker will finance a second year of grants, educational resources, and surveying for patients and caregivers.

Saturnus uses targeted gene modulation to address rare monogenetic cardiomyopathies with significant unmet need.

In a clinical trial, Redemplo led to a median 80 percent decrease in fasting triglyceride levels from baseline.